The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations (Q36521884)

14 August 2017

1 reference

title

The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations (English)

1 reference

14 August 2017

1 reference

1 reference

1 reference

Fabrizio Stocchi

1

0 references

language of work or name

English

0 references

publication date

1 July 2006

1 reference

Expert Opinion on Pharmacotherapy

14 August 2017

published in

1 reference

14 August 2017

volume

7

1 reference

14 August 2017

issue

10

1 reference

14 August 2017

page(s)

1399-1407

1 reference

Levodopa in the treatment of Parkinson's disease: current controversies

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Continuous dopamine-receptor stimulation in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Levodopa-induced dyskinesia: review, observations, and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Gastric emptying in Parkinson's disease: patients with and without response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Clinical-pathological study of levodopa complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Drug adherence in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Deficiency of both protein C and protein S in a family with ischemic strokes in young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Managing the critical problems of advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Continuous dopaminergic stimulation in early and advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

The role of COMT inhibition in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Clinical advantages of COMT inhibition with entacapone - a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Twelve-month safety of entacapone in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.7.10.1399

10.1517/14656566.7.10.1399

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference